- Funding solution aims to end three-year refusal to provide access to
treatment and care -
VANCOUVER, Feb. 23, 2013 /CNW/ - After more than three years of being
denied access to the care and treatment needed to protect the brains of
170 patients in B.C. with phenylketonuria (PKU), the Canadian PKU and
Allied Disorders Inc. (CanPKU) is asking Premier Christy Clark to
invest in a funding solution that will bring PKU care in the province
up to national, and international, standards and best practices. The
B.C. government has been screening every newborn baby for PKU since the
1960s,1 to allow treatment to begin immediately after the disease is detected;
however, many treatment options aren't accessible to PKU patients who
Today, at the annual B.C. PKU Day, families and patients living with the
rare, inherited and brain-threatening metabolic disorder gathered to
reconnect with the community and learn about developments in PKU
treatment and care from international experts. But the issue
top-of-mind for many attending the meeting, including Sparwood, B.C.
resident Nicole Pallone, is the government's refusal to fund the basic
treatments needed to protect the brains of PKU patients like Pallone's
five-year-old daughter, Rosie.
"We are shocked and appalled that the B.C. government continues to put
the health of our community at risk by denying patients access to
evidence-based, proven treatments that are the standard of care in most
developed countries," says Pallone, who is Vice President of CanPKU.
"For the past three years, the B.C. Ministry of Health has not only
turned its back on PKU patients, but has deliberately and
systematically avoided providing basic treatment for PKU patients in
this province - the same treatments that other governments right here
in Canada provide to their citizens."
Standard of PKU treatment in B.C. stagnant for 50 years
Despite exhaustive efforts by the PKU community, British Columbia is the
worst province in Canada for access to PKU treatments. The only public
funding that B.C. PKU patients receive is for special low-protein
formula,2 which has formed the basis of the complicated and highly-restrictive PKU
diet for the past 50 years. 3
Numerous provinces provide access to medical foods for PKU patients - a
key treatment necessary to prevent devastating neurocognitive,
psychiatric and physical symptoms caused by the disease. However, B.C.
only provides the bare minimum of coverage for the medical foods
necessary to manage PKU - a nominal $40 monthly stipend, available only
to PKU patients on social assistance.2
Three years ago, when Health Canada approved Kuvan (sapropterin) as the
first and only drug therapy for this brain-threatening disease,4 CanPKU began calling upon provincial and territorial governments to
fund the treatment for the 20 to 56 per cent of patients who respond to
it. While there has been positive movement towards funding agreements
in some provinces, such as Ontario where Kuvan will be publicly funded
as of February 28, 2013, B.C. is the only government to walk away from
negotiations with the drug's manufacturer.
However, the B.C. government does fund Kuvan to treat BH4 deficiency
(originally called malignant PKU), and as a diagnostic tool to
determine whether newborns with high Phe levels have PKU or BH4
"There is no question in my mind that PKU patients who have access to
the treatment combination of formula, medical foods and medication have
the greatest likelihood of healthy, productive lives, with minimized
negative health impacts," says Dr. Barbara Burton, director of the PKU
Clinic at the Ann and Robert H. Lurie Children's Hospital in Chicago,
who addressed B.C. PKU Day delegates on Saturday. "Many countries
around the world have accepted the body of clinical evidence and
professional consensus on the sustained health benefits of Kuvan and
medical foods, and are making those treatments accessible to patients."
Call for investment in Comprehensive Brain Protection Strategy
Faced with the B.C. government's continued indifference and
non-responsiveness to CanPKU's requests for funding, CanPKU has taken a
proactive approach by developing a policy paper to demonstrate to
government the minimal investment required to make a tangible
difference in the lives of PKU patients.
In a policy paper titled, A Comprehensive Brain Protection Strategy for People with PKU: Getting
BC from Worst to First, CanPKU has asked for an annual $2.8 million investment by the B.C.
government to improve treatment and care for PKU patients. Submitted to
the Premier and the Minister of Health on Friday, February 22, the
paper is composed of cost-effective, sustainable and realistic
solutions to ensure those British Columbians living with PKU have
access to all the necessary resources and treatments.
With this modest investment, CanPKU proposes that B.C.'s medical food
subsidy be brought up to standards comparable to Alberta, Saskatchewan,
Quebec and Ontario. It would also allow for the government to provide
dedicated funding for proven, innovative therapies, like Kuvan.
Additionally, the investment would enable a full-time psychologist, PKU
Clinic Coordinator, nurse and a part-time dietitian to be added to the
PKU/metabolic clinic team at B.C. Children's Hospital.
"We want to show that we're still willing to cooperate with government
to ensure protection for patients from the devastating health impacts
associated with PKU, while respecting budgetary constraints," says John
Adams, President and CEO of CanPKU, whose adult son has PKU. "There is
nothing unreasonable about our request - in fact, we think it's a no
brainer. This investment would represent about 0.1 per cent of the $2.4
billion in new health care funding over the next three years that was
just announced in B.C."
If approved, funding for the Comprehensive Brain Protection Strategy would be phased in over a three-year period to allow the government
time to more easily absorb the costs. CanPKU hopes that the 170 British
Columbians living with PKU would then finally have access to all the
available resources and treatments that will improve their health
outcomes and quality of life.
Adams adds that the longer funding is delayed, the longer the government
is needlessly putting the brains of PKU patients - from infants to
adults - at risk. "The time is now for the Premier to make good on her
stated commitment to 'Families First' by working with us to bring
treatment for PKU patients in this province from worst to first."
PKU (phenylketonuria) is a rare inherited, brain-threatening metabolic
disorder, observed when the body is unable to process phenylalanine
("Phe"), an essential amino acid found in dietary protein. The
resulting accumulation of Phe in the blood is toxic to the brain, and
if left untreated, symptoms can range from mild cognitive impairment to
severe mental retardation.5,6 Approximately 1 in 12,000 to 15,000 infants in Canada is born with PKU.7
About Canadian PKU and Allied Disorders Inc.
Canadian PKU and Allied Disorders Inc. is a non‐profit association of
volunteers, dedicated to providing accurate news, information and
support to families and professionals dealing with PKU and similar,
rare, inherited metabolic disorders. Our mission is to improve the
lives of people with PKU and allied disorders and the lives of their
families. By allied disorders we mean other rare, inherited metabolic
disorders also detected by newborn screening. For more information,
visit www.canpku.org and our new comprehensive resource for patients and families, PKU and the Brain.
Please join the conversation!
CanPKU on Twitter - follow our Tweets during our event today! #canpku
CanPKU on Facebook
CanPKU on YouTube
1 Canada lags on newborn screening. Canadian Medical Association.
Available at http://www.cmaj.ca/content/173/1/23.1.full. Accessed on January 18, 2012.
2 Canadian PKU and Allied Disorders Inc. Coverage for PKU Diet Formulas &
Medical Foods - May 2012. Accessed on January 29, 2013. Available at: http://www.canpku.org/images/pdf/coverage-pku-2012.pdf
3 Singh RH, Quirk ME. Using change in plasma phenylalanine concentrations
and ability to liberalize diet to classify responsiveness to
tetrahydrobiopterin therapy in patients..., Mol. Genet. Metab. (2011),
4 Kuvan [product monograph]. Toronto, ON: BioMarin Pharmaceutical
(Canada) Inc.; 2010.
5 Leuret O, Barth M, Kuster A et al. Efficacy and safety of BH4 before
the age of 4 years in patients with mild phenylketonuria. J Inherit
Metab Dis, 2012; DOI 10.1007/s10545-012-9464-3.
6 Martynyuk A et al., Epilepsy in Phenylketonuria: A Complex Dependence
on Serum Phenylalanine Levels. Epilepsia. 2007, 48(6):1143-50
7 Arnold GL. Phenylketonuria. 2009; http://emedicine.medscape.com/article/947781-print
Video with caption: "Families appeal for access to treatments for Canadian PKU patients". Video available at: http://stream1.newswire.ca/cgi-bin/playback.cgi?file=20130223_C7794_VIDEO_EN_23995.mp4&posterurl=http://photos.newswire.ca/images/20130223_C7794_PHOTO_EN_23995.jpg&clientName=Canadian%20PKU%20and%20Allied%20Disorders%20Inc%2E&caption=Families%20appeal%20for%20access%20to%20treatments%20for%20Canadian%20PKU%20patients&title=CANADIAN%20PKU%20AND%20ALLIED%20DISORDERS%20INC%2E%20%2D%20PKU%20Families%20ask%20Premier%20to%20invest%20in%20Comprehensive%20Brain%20Protection%20Strategy&headline=PKU%20Families%20ask%20Premier%20to%20invest%20in%20Comprehensive%20Brain%20Protection%20Strategy
Image with caption: "Poster - Premier Clark: To Harm or Protect? (CNW Group/Canadian PKU and Allied Disorders Inc.)". Image available at: http://photos.newswire.ca/images/download/20130223_C7794_PHOTO_EN_23980.jpg
PDF available at: http://stream1.newswire.ca/media/2013/02/23/20130223_C7794_DOC_EN_23985.pdf
PDF available at: http://stream1.newswire.ca/media/2013/02/23/20130223_C7794_DOC_EN_23986.pdf
PDF available at: http://stream1.newswire.ca/media/2013/02/23/20130223_C7794_DOC_EN_23987.pdf
PDF available at: http://stream1.newswire.ca/media/2013/02/23/20130223_C7794_DOC_EN_23988.pdf
PDF available at: http://stream1.newswire.ca/media/2013/02/23/20130223_C7794_DOC_EN_23996.pdf
SOURCE: Canadian PKU and Allied Disorders Inc.
For further information:
Cohn & Wolfe
416-924-5700 ext. 4070 (office)